Search
Lumicitabine
go.drugbank.com/drugs/DB14808InvestigationalLumicitabine is under investigation in clinical trial NCT03010059 (A Study to Assess the Relative Bioavailability of JNJ64041575 Administered as 2 Different New Concept Formulations (Oral Suspension and … Tablet) Compared to Their Respective Current Formulations, and to Assess the Effect of Food on the Pharmacokinetics of the 2 New Concept Formulations).
Multipotent adult arogenitor cells
go.drugbank.com/drugs/DB15742InvestigationalThe cells for creation of the product are isolated from a qualified donor and expanded on a large scale and then frozen until use. After administration, the cells are cleared from the body over time. … Additional benefits of MultiStem include their low immunogenicity, meaning they can be administered without tissue matching or concurrent immunosuppressive agents.
AVN-944
go.drugbank.com/drugs/DB05500InvestigationalAVN944 is a biotech drug that demonstrated a statistically meaningful impact on IMPDH and other proteins that are critical to activities in cancer cells, including nucleotide biosynthesis, energy and metabolism … It is being investigated for the treatment of patients with advanced hematologic malignancies.
Micronomicin
go.drugbank.com/drugs/DB13274ApprovedMicronomicin is an aminoglycoside antibiotic which is marketed in Japan, and sold under the brand names Sagamicin and Luxomicina.
Categories: Drugs that are Mainly Renally Excreted with a Narrow Therapeutic IndexAnti-SARS-CoV-2 equine immunoglobulin fragments
go.drugbank.com/drugs/DB16368Investigational[L27796] INOSARS is composed of F(ab’)2 fragments extracted from hyperimmune equine serum. … Anti-SARS-CoV-2 equine immunoglobulin fragments, also known as INOSARS, is a polyvalent passive immunization being tested in the clinical trial NCT04514302 (Safety and Efficacy of Anti-SARS-CoV-2 Equine
Synonyms: Anti-SARS-CoV-2 equine immunoglobulin fragments F(ab')2TB-402
go.drugbank.com/drugs/DB06050InvestigationalTB-402 is a human antibody binding to Factor VIII, which plays a crucial role in the coagulation of the blood. … It is expected to be developed as a potential treatment to prevent blood clot formation in connection with certain types of heart arrhythmia, such as atrial fibrillation.
AT1022
go.drugbank.com/drugs/DB04995ExperimentalAT1022 is a hydromorphone skin patch designed to provide rapid and sustained delivery of a potent opiate for the management of severe pain.
XP21279
go.drugbank.com/drugs/DB06319InvestigationalXP21279 is a prodrug of [Levodopa], a dopamine precursor used in the management of Parkinson's disease. … XP21279 was under investigation in clinical trial NCT00914602 (An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease Subjects), administered in combination with [Carbidopa
Luveltamab tazevibulin
go.drugbank.com/drugs/DB17563Investigational[A257414] It is under investigation in clinical trial NCT05200364 (A Study of STRO-002, an Anti-folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer … Luveltamab tazevibulin, formerly known as STRO-002, is novel homogeneous folate receptor alpha (FolRα) targeting antibody-drug conjugate.